<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="focused specifically on the intersection between the scientific efforts in" exact="hepatitis" post="B virus (HBV) and HIV-1 cure research and sought"/>
 <result pre="tissue samples required for the study of persistent virus HBV:" exact="hepatitis" post="B virus; cccDNA: covalently closed circular DNA. The keynote"/>
 <result pre="hepatic fibrosis and inflammation; •Decreased but not eliminated risk of" exact="hepatocellular carcinoma;" post="and •High cost and adverse effects of prolonged therapy."/>
 <result pre="clones (&amp;gt;10%), HIV-1 ISs were found to be enriched in" exact="cancer" post="genes, a result also consistent with the expansion resulting"/>
 <result pre="HBV DNA Viral genome in virus Active viral replication HBV:" exact="hepatitis" post="B virus. The loss of HBsAg is currently the"/>
 <result pre="advancing CAR-T cell therapy, which has rapidly gained popularity in" exact="cancer" post="[32] and antiviral therapy [33]. Indeed, lentivector-transduced T cells"/>
 <result pre="pre-screening for viral sensitivity [48] showed a more prolonged viral" exact="suppression" post="(median of 21 weeks) after ART interruption in antibody-sensitive"/>
 <result pre="Antibody-resistant viruses did not emerge and two individuals showed viral" exact="suppression" post="long after both bNAbs had been cleared (&amp;gt;30 months)."/>
 <result pre="same two bNAbs during acute HIV-1 infection resulted in sustained" exact="suppression" post="of viremia in a subset of animals. The effect"/>
 <result pre="viral load set-point. 5.1.4  Restoring or replacing adaptive immunity in" exact="hepatitis" post="B Turning the focus to HBV, Dr Mala Maini"/>
 <result pre="how an immunotherapeutic approach towards a functional cure for chronic" exact="hepatitis" post="B (CHB) should and could be tackled. Dr Maini"/>
 <result pre="of regulatory B cells mediates anti-HBV CD8 T cell response" exact="suppression" post="through IL-10 secretion [59]. Also, although HBsAg-specific B cells"/>
 <result pre="by T cell recognition. The platform has been developed for" exact="cancer" post="immunotherapy [66,67] and has multiple infectious disease applications in"/>
 <result pre="has been developed for cancer immunotherapy [66,67] and has multiple" exact="infectious disease" post="applications in development. Promising proof of concept from the"/>
 <result pre="on FX1, an inhibitor of the transcription factor B cell" exact="lymphoma" post="6 (BCL6) [70], Dr Yanhui Cai (Wistar Institute, Philadelphia,"/>
 <result pre="initiation. This compound is a sphingosine-1-phosphate receptor modulator used in" exact="multiple sclerosis" post="[73,74] that promotes the retention of several types of"/>
 <result pre="nonfunctional in mice and rats, but testing in the woodchuck" exact="hepatitis" post="model achieved lower levels of HBV surface antigen associated"/>
 <result pre="results from a dose escalation cohort in individuals with advanced" exact="hepatocellular carcinoma" post="offer some insight [80]. Overall, these results showed that"/>
 <result pre="5. Common community misconceptions about an HIV cure: •Complete viral" exact="suppression" post="is a cure and people may stop taking their"/>
 <result pre="is being developed. Relationships with potential clinical consequences such as" exact="hepatocellular carcinoma" post="in HBV carriers need to be taken into consideration."/>
 <result pre="Healthcare, the French National Agency for Research on AIDS and" exact="viral hepatitis" post="(ANRS), MSD and the Mexican Social Security Institute (IMSS)."/>
 <result pre="the French National Agency for Research on AIDS and viral" exact="hepatitis" post="(ANRS), MSD and the Mexican Social Security Institute (IMSS)."/>
 <result pre="formation of the covalently closed circular DNA persistence reservoir of" exact="hepatitis" post="B viruses. Proc Natl Acad Sci USA2014; 111(40): E4244–"/>
 <result pre="389.26983541 3.LuciforaJ, XiaY, ReisingerFet al.Specific and nonhepatotoxic degradation of nuclear" exact="hepatitis" post="B virus cccDNA. Science2014; 343(6176): 1221– 1228.24557838 4.UrbanS, BartenschlagerR,"/>
 <result pre="822.29045846 22.RevillPA, ChisariFV, BlockJMet al.A global scientific strategy to cure" exact="hepatitis" post="B. Lancet Gastroenterol Hepatol2019; 4(7): 545– 558.30981686 23.HuJ, ChengJ,"/>
 <result pre="23.HuJ, ChengJ, TangLet al.Virological basis for the cure of chronic" exact="hepatitis" post="B. ACS Infect Dis2019; 5(5): 659– 674.29893548 24.CoffinCS, ZhouK"/>
 <result pre="TerraultNA.New and old biomarkers for diagnosis and management of chronic" exact="hepatitis" post="B virus infection. Gastroenterology2019; 156(2): 355– 368. e353.30472225 25.BlockTM,"/>
 <result pre="of current and new endpoints in the evaluation of experimental" exact="hepatitis" post="B therapeutics. Clin Infect Dis2017; 64(9): 1283– 1288.28200098 26.RiddellJ,"/>
 <result pre="treatment of chronically infected patients and chimpanzees reveals that integrated" exact="hepatitis" post="B virus DNA is a source of HBsAg. Sci"/>
 <result pre="Nat Med2019; 25(2): 249– 254.30692695 39.BloomK, ElyA, MussolinoCet al.Inactivation of" exact="hepatitis" post="B virus replication in cultured cells and in vivo"/>
 <result pre="1897.23883864 40.ChenJ, ZhangW, LinJet al.An efficient antiviral strategy for targeting" exact="hepatitis" post="B virus genome using transcription activator-like effector nucleases. Mol"/>
 <result pre="ChettyS and BarthS.Principles of immunotherapy: implications for treatment strategies in" exact="cancer" post="and infectious diseases. Front Microbiol2018; 9: 3158.30622524 42.ShataMTM, Abdel-HameedEA,"/>
 <result pre="Hepatol2016; 64(1 Suppl): S71– S83.27084039 58.LewandowskaM and PiekarskaA.New directions in" exact="hepatitis" post="B therapy research. Clin Exp Hepatol2017; 3(3): 119– 126.29062901"/>
 <result pre="PallantCet al.IL-10-producing regulatory B cells in the pathogenesis of chronic" exact="hepatitis" post="B virus infection. J Immunol2012; 189(8): 3925– 3935.22972930 60.BurtonAR,"/>
 <result pre="McCoyLEet al.Circulating and intrahepatic antiviral B cells are defective in" exact="hepatitis" post="B. J Clin Invest2018; 128(10): 4588– 4603.30091725 61.BoniC, BariliV,"/>
 <result pre="E2754.31195619 62.MainiMK and PeppaD.NK cells: a double-edged sword in chronic" exact="hepatitis" post="B virus infection. Front Immunol2013; 4: 57.23459859 63.FabozziG, PeguA,"/>
 <result pre="73.CohenJA, BarkhofF, ComiGet al.Oral fingolimod or intramuscular interferon for relapsing" exact="multiple sclerosis." post="N Engl J Med2010; 362(5): 402– 415.20089954 74.KapposL, RadueEW,"/>
 <result pre="RadueEW, O’ConnorPet al.A placebo-controlled trial of oral fingolimod in relapsing" exact="multiple sclerosis." post="N Engl J Med2010; 362(5): 387– 401.20089952 75.MainiMK and"/>
 <result pre="Med2010; 362(5): 387– 401.20089952 75.MainiMK and PallettLJ.Defective T-cell immunity in" exact="hepatitis" post="B virus infection: why therapeutic vaccination needs a helping"/>
 <result pre="can be restored by blocking programmed death-1 pathway in chronic" exact="hepatitis" post="B. Gastroenterology2010; 138(2): 682– 693, 693.19800335 80.GaneE, VerdonDJ, BrooksAEet"/>
 <result pre="nivolumab with and without therapeutic vaccination for virally suppressed chronic" exact="hepatitis" post="B: a pilot study. J Hepatol2019: S0168-8278(19)30400-3 ( Epub"/>
</results>
